Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mesenchymal stem cell (MSC) transplantation is an experimental cell therapy being investigated by Assiut University for the treatment of Duchenne muscular dystrophy (DMD). DMD is a progressive genetic muscle-wasting disorder caused by the absence of the protein dystrophin. MSCs are multipotent stromal cells that possess significant immunomodulatory and anti-inflammatory properties, and they have the potential to differentiate into various cell types, including myogenic lineages. In clinical trials conducted at Assiut University Children Hospital, these cells are administered via intramuscular injection to evaluate their ability to reduce muscle inflammation, promote tissue repair, and slow the progression of both skeletal muscle disability and cardiomyopathy in affected boys.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mesenchymal stem cell transplantation (Assiut University).